Severe necrotizing myopathy after COVID-19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e100-e102. doi: 10.1111/jdv.17760. Epub 2021 Nov 3.

M Blaise¹, F Rocher², H Spittler³, A Sanchez¹, E Lanteri⁴, L Coco⁵, A Puma⁶, A Martel⁷, G Gonfrier⁸, T Passeron^{1

9}, H Montaudié^{1

9}

¹ Department of Dermatology, Université Côte d'Azur, Nice, France.
² Department of Pharmacology and Toxicology, PharmacoVigilance Center, Université Côte d'Azur, Nice, France.
³ Physical and Rehabilitation Medicine, Université Côte d'Azur, Nice, France.
⁴ Laboratory of clinical and experimental pathology, Université Côte d'Azur, Nice, France.
⁵ Department of Radiology, Université Côte d'Azur, Nice, France.
⁶ Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Université Côte d'Azur, Nice, France.
⁷ Department of Ophtalmology, Université Côte d'Azur, Nice, France.
⁸ Department of Virology, Université Côte d'Azur, CHU Nice, Nice, France.
⁹ INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.

No abstract available

Publication types